Skip to content

F Markus Leweke

4 papers in the library · publishing 2006-2009

Papers

Sort Most recent Most cited

The endocannabinoid system as a target for modelling psychosis.

Psychopharmacology November 1, 2009 Dagmar Koethe, Carolin Hoyer, F Markus Leweke

Model psychosis is characterised by experimentally induced symptoms of withdrawal from reality, frequently accompanied by perceptual disturbances, thought disorders, delusional ideas and sometimes by hallucinations. These "altered states of consciousness" provide a long-standing and valid approach to enhance our understanding of certain aspects of schizophrenia. Targeting the endocannabinoid...

Cannabis and psychiatric disorders: it is not only addiction.

Addiction Biology June 2008 F Markus Leweke, Dagmar Koethe

Since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the role of this system in major psychiatric disorders like schizophrenia (SCZ), bipolar disorder (BD), major depression and anxiety disorder. Continuing in the line of earlier epidemiological studies, recent replication studies indicate that frequent cannabis use doubles the risk...

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Schizophrenia Research August 2007 F Markus Leweke, Andrea Giuffrida, Dagmar Koethe et al.

Previous studies have shown that cerebrospinal fluid (CSF) from schizophrenic patients contains significantly higher levels of the endogenous cannabinoid anandamide than does CSF from healthy volunteers. Moreover, CSF anandamide levels correlated inversely with psychotic symptoms, suggesting that anandamide release in the central nervous system (CNS) may serve as an adaptive mechanism...

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness.

Schizophrenia Research December 1, 2006 Dagmar Koethe, Christoph W Gerth, Miriam A Neatby et al.

Recent data on alterations of the endogenous cannabinoid system in schizophrenia have raised the question of its functional role in this disease. The psychoactive compound of Cannabis sativa, delta-9-tetrahydrocannabinol (Delta9-THC), has been shown to induce psychotic symptoms, but it is unknown to what extend prodromal states of psychoses are reflected by these experimental approaches. This...